Dasatinib has been licensed for the treatment of chronic myeloid leukaemia (CML) with resistance or intolerance to imatinib mesylate. The National Institute for Health and Clinical Excellence (NICE) has not yet published guidance on the use of Dasatinib. Until NICE guidance is published, it is for primary care trusts (PCTs) to make decisions based on the evidence that is available on whether to fund drugs locally.
South East Coast strategic health authority has advised officials that Surrey, West Sussex and Hampshire Cancer Network has not produced any formal recommendations on the use of Dasatinib. It does, however, provide advice and recommendations to PCTs on an individual patient basis when requested to do so.